Physician profile
Robert A Centrone
NPI 1427060151
$22,282.05
in general payments reported to CMS, 2019-2025
61 companies · $4,584 in 2025
The $4,584 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,260 · 2020: $1,652 · 2021: $2,930 · 2022: $3,299 · 2023: $3,696 · 2024: $3,861 · 2025: $4,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,140.60 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,381.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,187.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,789.86 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,645.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,463.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,323.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,173.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,098.41 | 2019-2025 | Xifaxan, Cycloset |
| Novartis Pharmaceuticals Corporation | $713.01 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $700.43 | 2019-2025 | Jardiance, Tradjenta |
| Harmony Biosciences LLC | $683.57 | 2022-2025 | Wakix |
| Amarin Pharma, INC. | $601.31 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $558.81 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $493.15 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astellas Pharma US INC | $437.33 | 2019-2025 | Veozah, Myrbetriq |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $421.30 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $409.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $351.94 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $345.73 | 2019-2022 | |
| Axsome Therapeutics, INC. | $327.13 | 2022-2025 | Auvelity, Sunosi |
| Collegium Pharmaceutical, INC. | $216.47 | 2020-2025 | Xtampza, Belbuca |
| Biohaven Pharmaceutical Holding Company Ltd. | $196.01 | 2022 | |
| Eisai INC. | $179.48 | 2020-2025 | |
| Esperion Therapeutics, INC. | $176.27 | 2020-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $173.06 | 2021-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $162.52 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $161.05 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $154.49 | 2022-2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $137.54 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $123.29 | 2019-2025 | Trintellix |
| Seqirus USA INC | $110.74 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Indivior INC. | $108.27 | 2023-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.26 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $101.58 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $95.41 | 2023-2024 | Quviviq |
| Braeburn INC. | $74.50 | 2024-2025 | Brixadi |
| Abbott Laboratories | $69.41 | 2022-2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $63.19 | 2023-2025 | Loreev Xr, Gralise |
| E.R. Squibb & Sons, L.L.C. | $61.15 | 2023-2025 | Eliquis, Camzyos |
| Hikma Pharmaceuticals USA | $60.80 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $59.17 | 2019 | |
| Ardelyx, INC. | $58.78 | 2024-2025 | Ibsrela |
| Allergan, INC. | $57.10 | 2020 | |
| Dexcom, INC. | $56.22 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $55.67 | 2024 | Vivitrol |
| Lundbeck LLC | $50.66 | 2025 | Rexulti |
| Shield Therapeutics INC | $43.73 | 2024 | |
| Xeris Pharmaceuticals, INC. | $40.95 | 2022-2024 | Gvoke Hypopen |
| Phadia US INC. | $35.10 | 2020 | |
| Inspire Medical Systems, INC. | $20.62 | 2024 | Inspire |
| Evoke Pharma, INC. | $19.90 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.79 | 2022 | |
| Genentech USA, INC. | $17.24 | 2019 | |
| Radius Health, INC. | $16.90 | 2021 | |
| Gilead Sciences, INC. | $15.70 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.10 | 2021 | |
| Horizon Therapeutics Plc | $13.90 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.00 | 2021 | |
| Aytu Biopharma, INC. | $12.70 | 2020 | |
| Acadia Pharmaceuticals INC | $12.50 | 2019 | |
| Theracosbio, LLC | $12.31 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Centrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.